Valeant Pharmaceuticals International Inc. (VRX, VRX.TO) reported that its first-quarter net loss widened to $27.53 million or $0.09 per share, from $12.92 million or $0.04 per share in the same quarter last year.
Adjusted net income for the quarter was $405.16 million up from $360.32 million last year. Cash earnings per share increased to $1.30 from last year's $1.14. Cash earnings per share excluding one-time items was $1.30, up from $0.91 in the prior year.
Excluding gains on the divestiture of two dermatology products and a foreign exchange gain related to the acquisition of iNova in the first quarter of 2012, Cash earnings per share increased 43% over the year-ago quarter.
Total revenues were $1.068 billion, up from $856.10 million in the year ago quarter.
The company updated its previous Cash earnings per share guidance and is now targeting Cash earnings per share of $5.55 to $5.85 in 2013, despite a recent entry of Zovirax generic ointment, up from prior guidance of $5.45 to $5.75.
Total revenue in the range of $4.4 to $4.8 billion and adjusted cash flow from operations of $1.5 to $1.75 billion is reaffirmed.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.